• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

16 Biotechs I Like Even as a Lack of Liquidity Is Hurting the Market

Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.
By JAMES "REV SHARK" DEPORRE
Apr 07, 2021 | 01:20 PM EDT
Stocks quotes in this article: PSNL, PRQR, XERS, AUPH, SURF, ONCT, SEEL, GMDA, SIOX, PAVM, APEN, TRIL, ANIP, SAVA, FBRX, MYOV

Market players are struggling with something that they haven't seen in over 12 years -- a lack of liquidity.

Since the bear market of 2008-2009, the market's strength has often been explained with the simple phrase: "Don't fight the Fed." The view was that as long as the Fed is running its printing press, there would be plenty of cash to support equities.

The Fed is still quite dovish, and fiscal policy is at record levels as well, but what seems to be weighing on the market right now is a lack of liquidity. Fundamentals are fine, valuations are not terrible, and it is obvious that the economy is improving fast.

So where did all that liquidity that was driving the market a couple of months go? Some of it is sitting on the sidelines as traders have struggled for the last six weeks and lost confidence. Quite a bit of the cash is tied up in the flood of SPACs that soaked up billions. And some funds are flowing into consumption outside of the stock market.

This sort of poor trading action also tends to feed on itself. Buyers aren't going to jump in when price action is poor, and price action will stay poor if buyers aren't chasing strength.

I suspect we are just going through a form of corrective action and that the liquidity will come back again as the economy picks up speed. There shouldn't be any major tax hikes for a while, but that could be a roadblock at some point if liquidity isn't flowing very well.

I see quite a few stocks fading right now -- not due to poor fundamentals, but due to lack of buying interest. They can continue to drift lower, but the valuations are becoming quite compelling in places.

One group that is already beaten up and looks pretty washed out is biotechnology. Some of the names I'm tracking and watching for entry points are as follows:

Personalis (PSNL)

ProQR Therapeutics N.V. (PRQR)

Xeris Pharmaceuticals (XERS)

Aurinia Pharmaceuticals (AUPH)

Surface Oncology (SURF)

Oncternal Therapeutics (ONCT)

Seelos Therapeutics (SEEL)

Gamida Cell (GMDA)

Sio Gene Therapies (SIOX)

PAVmed Inc. (PAVM)

Apollo Endosurgery (APEN)

Trillium Therapeutics (TRIL)

ANI Pharmaceuticals (ANIP)

Cassava Sciences (SAVA)

Forte Biosciences (FBRX)

Myovant Sciences (MYOV)

There are quite a few interesting plays out there, but we need liquidity to return before they are going to do much.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long PSNL, PRQR, XERS, AUPH, SURF, ONCT, SEEL, GMDA, SIOX, PAVM, APEN, TRIL, ANIP, SAVA, FBRX, and MYOV.

TAGS: Drug Approvals | Federal Reserve | Investing | Markets | Politics | Small Cap | Stocks | Trading | Biotechnology

More from Stocks

Bearish Bets: 2 Stocks You Should Consider Shorting This Week

Bob Lang
Apr 11, 2021 10:32 AM EDT

These names are displaying both quantitative and technical deterioration.

Kass: On the Market's Stairway to Heaven, Headwinds Abound

Doug Kass
Apr 10, 2021 12:00 PM EDT

You can rock on for now while the music is still playing, but be prepared for the inevitable 'out of the blue' sour note.

The 5 Pillars of Exceptional Trading

James "Rev Shark" DePorre
Apr 10, 2021 10:00 AM EDT

When you put them together, trading success is nearly inevitable.

Market's 'Superficial' Highs Are Only Skin Dip

James "Rev Shark" DePorre
Apr 9, 2021 4:36 PM EDT

You can't call this market overbought when so much of it isn't participating.

Pinterest: Double Top or Breakout Pending?

Bruce Kamich
Apr 9, 2021 3:00 PM EDT

What would I do in this case? Here's the logical choice.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login